{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:13:08Z","timestamp":1781104388013,"version":"3.54.1"},"reference-count":26,"publisher":"Informa UK Limited","issue":"40","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.2217\/fon-2022-1117","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T10:02:28Z","timestamp":1679392948000},"page":"4509-4523","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Adverse Events and Clinical Outcomes in Patients Treated with PD-(L)1 Blockade for Advanced Non-Small-Cell Lung Cancer"],"prefix":"10.1080","volume":"18","author":[{"given":"Yan","family":"Zhang","sequence":"first","affiliation":[{"name":"Bristol Myers Squibb,\r3401 Princeton Pike,\rLawrence Township,\rNJ 08648,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Doran","sequence":"additional","affiliation":[{"name":"ConcertAI,\r6555 Quince, Suite 400,\rMemphis,\rTN 38119,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trong Kim","family":"Le","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,\r3401 Princeton Pike,\rLawrence Township,\rNJ 08648,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4241-9024","authenticated-orcid":false,"given":"Brian","family":"Dreyfus","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,\r3401 Princeton Pike,\rLawrence Township,\rNJ 08648,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Kola","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,\r3401 Princeton Pike,\rLawrence Township,\rNJ 08648,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke E","family":"Sylvester","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,\r3401 Princeton Pike,\rLawrence Township,\rNJ 08648,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lincy","family":"Lal","sequence":"additional","affiliation":[{"name":"ConcertAI,\r6555 Quince, Suite 400,\rMemphis,\rTN 38119,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Penrod","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,\r3401 Princeton Pike,\rLawrence Township,\rNJ 08648,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Meadows Shropshire","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,\r3401 Princeton Pike,\rLawrence Township,\rNJ 08648,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"e_1_3_5_4_1","unstructured":"US Food and Drug Administration . Oncology (cancer)\/hematologic malignancies approval notifications (2022). www.fda.gov\/drugs\/resources-information-approved-drugs\/oncology-cancer-hematologic-malignancies-approval-notifications (Accessed 7April2022)."},{"key":"e_1_3_5_5_1","unstructured":"National Comprehensive Cancer Network (NCCN) . NCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer (2022). www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450 (Accessed 15September2022)."},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061388"},{"key":"e_1_3_5_7_1","unstructured":"Bristol-Myers Squibb . Study of nivolumab (BMS-936558) in patients with advanced or metastatic squamous cell nonsmall-cell lung cancer who have received at least 2 prior systemic regimens (2021). (NLM Identifier: NCT01721759). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01721759 (Accessed 23May2022)."},{"key":"e_1_3_5_8_1","unstructured":"Hoffman-La Roche . A randomized phase 2 study of atezolizumab (an engineered anti-PDL1 antibody) compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer who have failed platinum therapy \u2013 \u2018POPLAR\u2019 (2019). (NLM Identifier: NCT01903993). http:\/\/clinicaltrials.gov\/show\/NCT01903993 (Accessed 8April2022)."},{"key":"e_1_3_5_9_1","unstructured":"Merck Sharp & Dohme Corp . Study of two doses of pembrolizumab (MK-3475) versus docetaxel in previously treated participants with non-small cell lung cancer (MK-3475-010\/KEYNOTE-010) (2021). (NLM Identifier: NCT01905657). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01905657 (Accessed 23May2022)."},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00730"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000457"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030546"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx380.025"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.004"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01549-2"},{"issue":"46","key":"e_1_3_5_18_1","first-page":"938","article-title":"Chronic obstructive pulmonary disease among adults \u2013 United States, 2011.","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","unstructured":"Centers for Disease Control and Prevention . Chronic obstructive pulmonary disease among adults \u2013 United States, 2011.MMWR Morb. Mortal. Wkly Rep.61(46), 938\u2013943 (2012).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0348"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13812"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx181"},{"issue":"1","key":"e_1_3_5_22_1","doi-asserted-by":"crossref","first-page":"e000477","DOI":"10.1136\/esmoopen-2018-000477","article-title":"Early use of steroids affects immune cells and impairs immunotherapy efficacy.","volume":"4","author":"Della Corte CM","year":"2019","unstructured":"Della Corte CM , MorgilloF. Early use of steroids affects immune cells and impairs immunotherapy efficacy.ESMO Open4(1), e000477 (2019).","journal-title":"ESMO Open"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.12.012"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470258019"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.11.710"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"e_1_3_5_27_1","unstructured":"National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): management of immunotherapy-related toxicities.Version 3.2021 (2021). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.03.017"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-1117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:52Z","timestamp":1719125212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-1117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":26,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.2217\/fon-2022-1117"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-1117","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}